Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Sickle Cell Disease Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.0% during the forecast period.
This report presents the market size and development trends by detailing the Sickle Cell Disease Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Sickle Cell Disease Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Sickle Cell Disease Drug industry and will help you to build a panoramic view of the industrial development.
Sickle Cell Disease Drug Market, By Type:
ARQ-092
BIVV-003
CAL-H
CTX-001
DRX-194
Others
Sickle Cell Disease Drug Market, By Application:
Hospital
Clinic
Others
Some of the leading players are as follows:
Bristol-Myers Squibb Co
Acceleron Pharma Inc
Editas Medicine Inc
Annexin Pharmaceuticals AB
Calimmune Inc
Global Blood Therapeutics Inc
Gilead Sciences Inc
bluebird bio Inc
Bio Products Laboratory Ltd
Genethon SA
Addmedica SAS
ArQule Inc
Gamida Cell Ltd
Errant Gene Therapeutics LLC
CSL Ltd
Angiocrine Bioscience Inc
CRISPR Therapeutics
Bioverativ Inc
Daiichi Sankyo Co Ltd
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Sickle Cell Disease Drug Market: Technology Type Analysis
-
4.1 Sickle Cell Disease Drug Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Sickle Cell Disease Drug Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 ARQ-092
4.3.2 BIVV-003
4.3.3 CAL-H
4.3.4 CTX-001
4.3.5 DRX-194
4.3.6 Others
5 Sickle Cell Disease Drug Market: Product Analysis
-
5.1 Sickle Cell Disease Drug Product Market Share Analysis, 2018 & 2026
-
5.2 Sickle Cell Disease Drug Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Sickle Cell Disease Drug Market: Application Analysis
-
6.1 Sickle Cell Disease Drug Application Market Share Analysis, 2018 & 2026
-
6.2 Sickle Cell Disease Drug Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
7 Sickle Cell Disease Drug Market: Regional Analysis
-
7.1 Sickle Cell Disease Drug Regional Market Share Analysis, 2018 & 2026
-
7.2 Sickle Cell Disease Drug Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Bristol-Myers Squibb Co
9.1.1 Bristol-Myers Squibb Co Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Acceleron Pharma Inc
9.2.1 Acceleron Pharma Inc Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Editas Medicine Inc
9.3.1 Editas Medicine Inc Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Annexin Pharmaceuticals AB
9.4.1 Annexin Pharmaceuticals AB Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Calimmune Inc
9.5.1 Calimmune Inc Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Global Blood Therapeutics Inc
9.6.1 Global Blood Therapeutics Inc Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Gilead Sciences Inc
9.7.1 Gilead Sciences Inc Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 bluebird bio Inc
9.8.1 bluebird bio Inc Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Bio Products Laboratory Ltd
9.9.1 Bio Products Laboratory Ltd Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Genethon SA
9.10.1 Genethon SA Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Addmedica SAS
9.11.1 Addmedica SAS Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 ArQule Inc
9.12.1 ArQule Inc Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Gamida Cell Ltd
9.13.1 Gamida Cell Ltd Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Errant Gene Therapeutics LLC
9.14.1 Errant Gene Therapeutics LLC Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 CSL Ltd
9.15.1 CSL Ltd Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Angiocrine Bioscience Inc
9.16.1 Angiocrine Bioscience Inc Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 CRISPR Therapeutics
9.17.1 CRISPR Therapeutics Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
9.18 Bioverativ Inc
9.18.1 Bioverativ Inc Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis
9.19 Daiichi Sankyo Co Ltd
9.19.1 Daiichi Sankyo Co Ltd Company overview
9.19.2 Financial performance
9.19.3 Product benchmarking
9.19.4 Strategic initiatives
9.19.5 SWOT analysis
The List of Tables and Figures (Totals 62 Figures and 165 Tables)
Figure ARQ-092 Sickle Cell Disease Drug market, 2015 - 2026 (USD Million)
Figure BIVV-003 Sickle Cell Disease Drug market, 2015 - 2026 (USD Million)
Figure CAL-H Sickle Cell Disease Drug market, 2015 - 2026 (USD Million)
Figure CTX-001 Sickle Cell Disease Drug market, 2015 - 2026 (USD Million)
Figure DRX-194 Sickle Cell Disease Drug market, 2015 - 2026 (USD Million)
Figure Others Sickle Cell Disease Drug market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Clinic market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Sickle Cell Disease Drug market, by country, 2015 - 2026 (USD Million)
-
Table North America Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table North America Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table North America Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Canada Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Canada Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Europe Sickle Cell Disease Drug market, by country, 2015 - 2026 (USD Million)
-
Table Europe Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Europe Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Europe Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Germany Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Germany Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table France Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table France Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Italy Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Italy Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Spain Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Spain Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Sickle Cell Disease Drug market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table China Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table China Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Japan Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Japan Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table India Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table India Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Sickle Cell Disease Drug market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table MEA Sickle Cell Disease Drug market, by country, 2015 - 2026 (USD Million)
-
Table MEA Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table MEA Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table MEA Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Sickle Cell Disease Drug market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Sickle Cell Disease Drug market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Sickle Cell Disease Drug market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Bristol-Myers Squibb Co Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Acceleron Pharma Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Editas Medicine Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Annexin Pharmaceuticals AB Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Calimmune Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Global Blood Therapeutics Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Gilead Sciences Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table bluebird bio Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bio Products Laboratory Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Genethon SA Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Addmedica SAS Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table ArQule Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Gamida Cell Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Errant Gene Therapeutics LLC Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table CSL Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Angiocrine Bioscience Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table CRISPR Therapeutics Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bioverativ Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Daiichi Sankyo Co Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
